Engflag

Kymriah

Quick links to important sections

Kymriah

Kymriah_ET

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Kymriah

Property Description
Active ingredient Tisagenlecleucel (CAR-positive viable T cells)
Form Dispersion / Cell Suspension for intravenous infusion
Pharmacological class CD19-directed genetically modified autologous T-cell immunotherapy
Origin Autologous (Derived from the patient's own cells)
Manufacturer Novartis Pharmaceuticals Corporation

What is Tisagenlecleucel: An Individualized CAR T-Cell Therapy?

Kymriah is the brand name for the active ingredient tisagenlecleucel, which is classified as a highly specialized CD19-directed genetically modified autologous T-cell immunotherapy. This advanced biological product belongs to the pharmacological class of CAR T-cell therapy, representing a significant breakthrough in cell and gene therapy.

The defining characteristic of Kymriah is its autologous origin, meaning the therapeutic cells are derived and manufactured exclusively from the patient’s own T lymphocytes. Tisagenlecleucel is also categorized as a form of gene therapy because it involves the permanent modification of these cells outside the body, transforming them into a highly focused therapeutic agent.

The Composition and Origin of Kymriah

The active component, tisagenlecleucel, consists of the patient's own T cells that have been engineered to express a Chimeric Antigen Receptor (CAR) on their surface. This specialized CAR is the crucial targeting mechanism, designed to recognize the CD19 protein, which is found on the surface of the targeted cells. The manufacturer, Novartis Pharmaceuticals Corporation, manages the complex process required to create this individualized medicine.

The final product is supplied as a cell suspension for intravenous infusion, the necessary pharmaceutical form for administering these highly modified cellular agents systemically. The autologous nature of the T cells ensures maximal immune compatibility with the recipient.

How Does CAR T-Cell Therapy Serve its General Purpose?

The Tisagenlecleucel therapy's general purpose is to deploy the reprogrammed immune system to systematically seek out and eliminate the cell population expressing the CD19 protein. The integrated CAR T-cells activate and multiply upon encountering the CD19 marker, initiating a robust and precise immune response.

This highly focused action is the core design principle of Kymriah, as this cellular approach is intended to provide a durable therapeutic presence and sustained clearance of the designated target cell population, forming the basis of its therapeutic use.

Regulatory References

  1. Kymriah | European Medicines Agency (EMA)
  2. What is Gene Therapy? - MedlinePlus Genetics

What side effects are possible with Kymriah?

Possible side effects and safety information

The safety profile of tisagenlecleucel (Kymriah) is defined by serious immune-mediated toxicities resulting from the activation and expansion of the modified T-cells, alongside hematologic and infectious risks. Adverse reactions are classified according to frequency and the body system affected, as documented in regulatory labeling (e.g., EMA SmPC, FDA Prescribing Information).

Key Serious Adverse Reactions

The official label highlights the potential for severe or life-threatening reactions. These include:

  • Cytokine Release Syndrome (CRS): This is a potentially life-threatening reaction that typically begins within the first ten days after infusion, involving symptoms such as fever, hypotension, and hypoxia.
  • Neurological Toxicities (ICANS): Severe nervous system effects, including Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), seizures, and encephalopathy, may occur, mostly within eight weeks post-infusion.
  • Hemophagocytic Lymphohistiocytosis (HLH)/Macrophage Activation Syndrome (MAS).
  • Serious Infections and Prolonged Cytopenias (low blood cell counts).
  • Secondary Malignancies have been reported, necessitating long-term patient monitoring.

Common Adverse Reactions and Systemic Effects

Many adverse effects are classified as Very Common (occurring in ge 1/10 patients) in regulatory documents. These frequently involve the following systems:

  • General/Systemic: Fever (Pyrexia), fatigue, and decreased appetite.
  • Hematologic: Neutropenia, thrombocytopenia, and anemia.
  • Immune System: Hypogammaglobulinaemia and infusion-related reactions.
  • Gastrointestinal: Nausea, vomiting, and diarrhea.

Population and Exposure-Related Safety Notes

High pre-infusion tumor burden is noted as a risk factor for severe CRS in pediatric and adult patients. The treatment carries a theoretical risk of fetal B-cell lymphocytopenia if administered during pregnancy. The infusion may be delayed if a patient has an active uncontrolled infection or unresolved serious adverse reactions from prior therapies. Due to certain risks, the product is available through a restricted distribution program and requires specialized long-term follow-up.

Overdose and Emergency Response

Overdose and when to seek help

The regulatory information for Tisagenlecleucel addresses an overdosage of cells as a risk factor for the potentiation of the product’s severe toxicities, rather than traditional chemical overdose. This involves an exacerbation of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS).

Property Official Regulatory Documentation
Documented overdose presentations Exacerbation of CRS signs (pyrexia, severe hypotension, hypoxia, chills) and ICANS manifestations (encephalopathy, seizures, confusion, speech disorders).
Physiological systems affected Central Nervous System, Cardiovascular System, Respiratory System, Renal System.
Population-specific overdose notes The cellular threshold for overdosage is defined relative to the specific weight-based and non-weight-based dosing ranges for different patient populations.
When immediate medical help is required Urgent medical attention is required for signs and symptoms of severe CRS or Neurological Toxicities.

Official overdose statements:

  • Overdosage carries the risk of life-threatening or fatal events.
  • No specific antidote for the cellular product is documented in the official regulatory labeling.
  • Seek immediate medical attention and be immediately evaluated for hospitalization at the first sign of severe symptoms.
  • Management involves the mandated use of specific agents, including Tocilizumab and corticosteroids, alongside supportive treatment.

The overall overdose profile is defined by the high severity of its potential manifestations and the explicit, regulator-mandated requirement for immediate emergency medical assistance. The management is procedural, relying on standardized supportive interventions documented within the official label.

Therapeutic Uses of Kymriah

The therapy is generally used to address conditions presenting with systemic blood malignancies that have proven treatment-resistant. This treatment is considered relevant for two main areas: B-cell Acute Lymphoblastic Leukaemia (ALL) in children and young adults (up to 25 years old) that is refractory or in second or later relapse, and Diffuse Large B-cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) in adults whose cancer has returned or was unresponsive after two or more prior lines of systemic therapy.

The clinical scenario is often one of high unmet need. The therapy is applied when the cancer is refractory or has undergone a second or later relapse, meaning patients are facing a high disease burden after failing multiple prior systemic therapies. The use is relevant for supporting sustained disease stability.

“The therapy is applied across domains where additional symptomatic support is needed in complex treatment histories.”

The therapy may support easing the systemic symptoms related to the malignancy, which may assist patients with maintaining functional stability in situations where prior treatments have been ineffective. This may also contribute to managing the overall symptom load associated with advanced cancer.

Quick Fact: Relevant for Managing Symptomatic Burden The therapy is commonly used in conditions presenting with significant symptomatic burden after multiple previous treatment failures, and plays a role in managing symptoms that interfere with daily functioning.

Regulatory References

  1. European Medicines Agency product information on Kymriah

Eligibility and Restrictions for Use

Kymriah (tisagenlecleucel) is a cell-based gene therapy product with specific eligibility criteria defined by regulatory documents for its approved uses.

Populations Eligible for Use

  • Pediatric and Young Adult B-cell ALL: Patients up to 25 years of age with B-cell precursor Acute Lymphoblastic Leukemia (ALL) that is refractory (did not respond to treatment) or in second or later relapse.
  • Adult B-cell Lymphoma: Adult patients with relapsed or refractory (r/r) large B-cell lymphoma (including DLBCL) or follicular lymphoma (FL) after two or more lines of systemic therapy.

Eligibility Restrictions and Contraindications

  • Contraindication: No formal contraindications are listed in the U.S. FDA Prescribing Information, but some regulatory bodies list known hypersensitivity to the drug or its components as a contraindication.
  • Use Not Recommended/Prohibited: Do not administer Kymriah to patients with active infection or inflammatory disorders.
  • Delay of Infusion: The infusion must be delayed in patients with unresolved serious adverse reactions from preceding chemotherapy, active uncontrolled infection, active Graft versus Host Disease (GVHD), or worsening leukemia burden after lymphodepleting chemotherapy.
  • Exclusion: The drug is not indicated for the treatment of patients with primary central nervous system lymphoma. Additionally, leukapheresis material from patients with a positive test for HIV, active HBV, or active HCV infection will typically not be accepted for product manufacturing.
  • Pregnancy/Lactation: Kymriah is not recommended for women who are pregnant or breastfeeding, as safety and efficacy data for this population are not available.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Kymriah (tisagenlecleucel) primarily concerns agents that affect the immune system and medicines used to manage treatment-related side effects. Official regulatory documents outline several important restrictions and requirements to protect the CAR-T cell activity and manage severe toxicities.

Category Interaction Restriction/Requirement
Systemic Corticosteroids Avoid prophylactic use, as it may interfere with the activity and function of Kymriah. Use only for treating severe or life-threatening toxicities, such as high-grade Cytokine Release Syndrome (CRS).
Live Vaccines Do not administer for at least 6 weeks before infusion and until immune recovery is confirmed after treatment. This is due to the risk of serious infection and potential interference with Kymriah activity.
CRS Management The anti-cytokine therapy tocilizumab must be readily available on-site prior to Kymriah infusion for the management of moderate or severe CRS. Other Tumor Necrosis Factor (TNF) antagonists are not recommended for managing CRS.
Premedication Patients are premedicated with acetaminophen and an H1-antihistamine approximately 30 to 60 minutes prior to infusion to minimize acute infusion reactions.

Patients with persistent low immunoglobulin levels (hypogammaglobulinemia), which is a possible reaction, may be recommended to receive replacement therapy. Patients treated with Kymriah are advised not to donate blood, organs, tissues, or cells for transplantation.

Mechanism of Action

Ontology: How Kymriah Works

Engineered Recognition and Activation

This mechanism relies on altering autologous T-cells by equipping them with a Chimeric Antigen Receptor (CAR), which functions as a synthetic recognition system. The CAR is programmed to bind specifically to the CD19 antigen on target cells, an action independent of the Major Histocompatibility Complex (MHC). Upon binding, the internal CD3zeta and 4 -1 BB domains are activated, initiating a cascade of T-cell proliferation and differentiation.

Systemic Cytotoxicity and B-cell Depletion

Once activated, the modified T-cells rapidly multiply and deploy their innate killing machinery by secreting molecules like perforin and granzymes. This leads to direct cell-mediated cytotoxicity and the subsequent lysis (destruction) of CD19-expressing cells across affected systems. The resulting physiological consequence is the systemic depletion of the B-cell lineage.

Mechanism Function and Constraints

The inclusion of the 4 -1 BB costimulatory domain supports the persistence and survival of the modified T-cells, enabling sustained cell function. However, the mechanism is constrained by factors such as potential antigen escape (loss of CD19 on target cells) and T-cell exhaustion, which influences the continuity of the resulting physiological effect.

Dosage and Administration Information

Kymriah (tisagenlecleucel) is a highly specialized, autologous T-cell immunotherapy that requires a precise, multi-stage process for administration. The medicine is provided as a single-dose cell suspension for intravenous infusion and is never administered via any other route.

Dosing and Schedule

The dosage is uniquely determined by the number of CAR-positive viable T cells. Dosing for pediatric patients le 50 kg (in B-cell Acute Lymphoblastic Leukaemia) is weight-based, ranging from 0.2 to 5.0 imes 10^6 cells per kilogram. For adults and young adults > 50 kg, the dose is non-weight-based, with specified total cell ranges (e.g., 0.6 to 6.0 imes 10^8 total cells for Diffuse Large B-cell Lymphoma).

The entire therapeutic course is a one-time administration that is not repeated. The infusion must be performed after the patient has completed a mandatory course of lymphodepleting chemotherapy. The interval between the completion of lymphodepletion and the Kymriah infusion is strictly defined, generally spanning 2 to 14 days, depending on the indication.

Administration Conditions

Due to the cell product's sensitivity, strict handling and administration conditions apply. Patients are required to receive premedication (acetaminophen and an H1-antihistamine) approximately 30 to 60 minutes before the infusion. The cryopreserved bag must be thawed at the treatment center and, once at room temperature, the product must be administered within a 30-minute window. The infusion must not use a leukocyte-depleting filter and the line is rinsed with 0.9% Sodium Chloride solution to ensure the full dose is delivered.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Kymriah

The clinical evidence for Kymriah's authorized uses is based primarily on pivotal, single-arm clinical trials that examine how patients responded to the therapy in settings where prior treatments have not worked. Because the therapy was studied for high-risk cancers, the initial research focused on measuring responses shortly after infusion.

Evidence for B-cell Acute Lymphoblastic Leukaemia (ALL)

The main research was conducted in a global Phase II study (ELIANA trial), which followed an open-label, single-arm design. This research was evaluated in paediatric and young adult patients (up to age 25) whose ALL was refractory or had returned after multiple prior lines of therapy. Researchers monitored primary outcomes such as the Overall Remission Rate (ORR), Minimal Residual Disease (MRD) status, and long-term measures like Relapse-Free Survival (RFS) and Overall Survival (OS).

Studies reported measurements of remission (CR/CRi) in the observed populations. Pivotal trial data reported patterns where responders had MRD negative status in bone marrow. Updated long-term data include measurements of survival outcomes and remission durability for patients tracked for over five years.

Evidence for Diffuse Large B-cell Lymphoma (DLBCL)

The primary data for this use comes from another global, multicenter single-arm Phase II trial (JULIET study) evaluated in adult patients with aggressive DLBCL that had relapsed or was refractory after they had failed two or more prior lines of systemic therapy. The key response measures tracked were the Overall Response Rate (ORR) and the Complete Response Rate (CRR).

Studies reported measurements of response, reporting patterns where a portion of the treated adults had a Complete Response (CR). Updated data over more than three years include measurements of the duration of responses and long-term survival patterns observed in the studied population.

Evidence Gaps and Areas of Uncertainty

The research on Kymriah has several key limitations that are acknowledged in scientific literature. First, comparative evidence is lacking, as the pivotal trials for all approved indications were designed as single-arm studies without a control group. Second, follow-up durations were limited for the initial approval, and while long-term updates are available, the full characterization of patient outcomes over a 15-year period is still emerging from mandatory post-approval surveillance. Research provides context but not individual predictions.

Key Studies & References

  1. European Medicines Agency (EMA): Kymriah - EPAR Product Information
  2. National Institute for Health and Care Excellence (NICE): Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia
  3. National Institute for Health and Care Excellence (NICE): Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma

Frequently Asked Questions (FAQ)

Common questions about Kymriah (FAQ)

Q: How long does the Kymriah infusion take?

According to the official product information, the infusion itself is generally completed in less than one hour. Due to the specific handling needs of the cell product, official guidance specifies the infusion should be completed within a 30-minute window once the cryopreserved bag has been thawed and brought to room temperature.

Q: What are the common symptoms of Cytokine Release Syndrome (CRS)?

Regulatory documents state that Cytokine Release Syndrome (CRS) is a potentially serious side effect. Common symptoms may include fever, chills, difficulty breathing, severe nausea, vomiting, or diarrhea, very low blood pressure, and dizziness.

Q: What is the age limit for adult patients with Diffuse Large B-cell Lymphoma (DLBCL)?

Official information indicates that Kymriah is indicated for adult patients with Diffuse Large B-cell Lymphoma (DLBCL). The product label specifies the indication for adult patients, typically defined as those 18 years of age and older. No specific upper age limit is listed in the official indication for this type of lymphoma.

Q: What are the requirements for the treatment facility that administers Kymriah?

Because of potential serious risks, Kymriah is administered only through a restricted distribution program. The therapy is administered at specialized treatment centers that meet specific safety requirements, including the immediate availability of specific medications like tocilizumab and emergency equipment.

Q: How long after administration do the side effects typically last?

The onset and duration of side effects vary. Cytokine Release Syndrome (CRS) typically starts within the first 10 days, and neurological toxicities mostly occur within 8 weeks after the infusion. Some side effects, such as hypogammaglobulinemia (low antibody levels), can be prolonged and may require long-term management.

How should Kymriah be stored and disposed of?

How to Store and Dispose of Kymriah

Kymriah (tisagenlecleucel) requires strict environmental controls due to its nature as a cryopreserved cellular therapy.

Official Storage and Stability Requirements

Requirement Condition (Regulatory Mandate)
Initial Storage Must be stored continuously in the vapor phase of liquid nitrogen at -150 C or below.
Container Rule The patient-specific infusion bag must be inspected for cracks before thawing; a compromised bag must not be infused.
Post-Thaw Stability Once thawed and at room temperature (20 C to 25 C), infusion must be completed within 30 minutes.

Handling and Disposal Rules

Kymriah must be thawed at 37 C immediately prior to infusion, one bag at a time. The product contains human cells genetically modified with a lentivirus. Therefore, the disposal of any unused or expired product, and all materials that contact it, must strictly follow local biosafety guidelines applicable to genetically modified cellular products and infectious waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Kymriah found in:

A-Z Index: